A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 498 participants.

Also called NCT01590771

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 498 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01590771
Main results
  • Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin Journal of diabetes, 2017-07 DOI, PubMed 27502307

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01590771. Randomized; triple masking; primary purpose treatment. Start 2012-07-09 (actual); primary completion 2014-06-10 (actual). Results posted on 2015-05-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Drug)
Gliclazide
Intervention (Drug)
Glimepiride
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01590771
Content hash
5b524faa3bc0e09e2b50b15fe04c1b8dce76e51a068ac2ccc5e257da09210110